Mortality and Its Predictors among Adult Human Immune-Deficiency Virus-Infected Patients Attending Their Antiretroviral Treatment at Health Centers, Addis Ababa, Ethiopia: Multicenter Retrospective Cohort Study
Table 2
Clinical characteristics of patients under ART in health centers at Kirkos subcity Addis Ababa, Ethiopia, 2014–2019.
Variables
Frequency
Percentage
Baseline hemoglobin (g/dl) mean (±SD)
13.25 (±3.16)
<10
33
5.4
≥10
577
94.6
Active TB during treatment
No
470
76.7
Yes
143
23.3
WHO clinical stages
Stage I
277
45.2
Stage II
145
23.7
Stage III
94
15.3
Stage IV
97
15.8
Base line CD4+ (cells/μl) mean (±SD) (n = 613)
391.2 (±143.5)
<200
67
10.9
≥200
546
89.1
Functional status
Working
401
65.4
Ambulatory
168
27.4
Bedridden
44
7.2
Drug allergy
No
376
61.3
Yes
237
38.7
Drug adherence
No
157
25.6
Yes
456
74.4
Body mass index
<18.5
183
29.9
≥18.5
428
69.8
Baseline ART regimen
ABC + 3TC + EFV
96
15.7
TDF-3TC-EFV
488
79.6
Others
29
4.7
Change in the ART regimen from baseline
No
531
86.6
Yes
82
13.4
Co-trimoxazole therapy
No
350
57.1
Yes
262
42.7
Note. ART-antiretroviral therapy, ABC-abacavir, 3TC-lamivudine, EFV-efavirenz, and TDF-tenofovir disoproxil fumarate.
